Phase 3 Readout
AZN: Phase 3 Topline: A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Inves
June 19, 2026 · trastuzumab. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- June 19, 2026
- Company
- ASTRAZENECA PLC (AZN)
- Drug
- trastuzumab
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Inves
- Company
- ASTRAZENECA PLC (AZN)
- Drug
- trastuzumab
- Indication
- Advanced or Metastatic Breast Cancer
Other upcoming events for AZN
Phase 3 ReadoutPhase 3 Topline: A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoe
Phase 3 ReadoutPhase 3 Topline: A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination With Chemothera
Phase 3 ReadoutPhase 3 Topline: A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combinati
Phase 3 ReadoutPhase 3 Topline: A Phase IIIb Single Arm, Open-label, Multicentre Study of Durvalumab and Tremelimumab as First Line
Phase 3 ReadoutPhase 3 Topline: A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compa